Novocure Announces Preliminary Full Year and Fourth Quarter 2022 Net Revenues and Provides Company Update

Author's Avatar
Jan 09, 2023

Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial results and operational updates for the quarter and full year ended December 31, 2022. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields).